Endo Health Solutions : ENDP

All ENDP Articles

103 Articles

Paul Ausick | Mar 15, 2016 at 4:04 PM EDT

The 52-Week Low Club for Tuesday

March 15, 2016: Here are four stocks trading with heavy volume among 33 equities making new 52-week lows in Tuesday’s…

Paul Ausick | Mar 10, 2016 at 4:01 PM EST

The 52-Week Low Club for Thursday

March 10, 2016: Here are four stocks trading with heavy volume among 45 equities making new 52-week lows in Thursday’s…

Paul Ausick | Feb 29, 2016 at 4:04 PM EST

The 52-Week Low Club for Monday

February 29, 2016: Here are four stocks trading with heavy volume among 30 equities making new 52-week lows today. Endo…

Jon C. Ogg | Jan 21, 2016 at 8:55 AM EST

Top Analyst Upgrades and Downgrades: GE, 3M, Shopify, SunPower, Zafgen, CIT, Ericsson, Honeywell and Many More

Thursday's top analyst calls include General Electric, 3M, Shopify, SunPower, Zafgen, CIT, Ericsson, Honeywell.

Lee Jackson | Dec 29, 2015 at 10:55 AM EST

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016

These specialty pharmaceutical stocks have tremendous upside potential for 2016 and could be offering investors outstanding entry points at current…

Lee Jackson | Dec 3, 2015 at 8:25 AM EST

Top RBC Stock Picks With as Much as 100% Upside Potential

The RBC U.S. Equity Top Picks list has handily outperformed the S&P 500 this year and since inception.

Jon C. Ogg | Nov 16, 2015 at 8:15 AM EST

Top Analyst Upgrades and Downgrades: Best Buy, CA, Deere, Eli Lilly, Ferrari, Netflix, Oracle, Salesforce.com and More

Monday's top analyst upgrades, downgrades and initiations include Best Buy, CA, Deere, Eli Lilly, Ferrari, Netflix, Oracle and Salesforce.com.

Paul Ausick | Oct 31, 2015 at 10:25 AM EDT

10 Worst Performing Stocks in October

Some stocks have had a tough quarter and continued to struggle through October. These are the month's 10 worst-performing S&P…

Chris Lange | Oct 31, 2015 at 10:10 AM EDT

6 BioPharma Movers That Cannot Be Ignored

Last week, a few biotech companies made absolutely massive runs, and some had serious falls.

Lee Jackson | Oct 28, 2015 at 10:35 AM EDT

With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains

With specialty pharmaceutical stocks having the chance to move dramatically higher, three large cap leaders are RBC's favorites now.

Chris Lange | Oct 26, 2015 at 8:45 AM EDT

How an FDA Approval Changes the Game for Endo and BioDelivery Sciences

Endo International and BioDelivery Sciences have announced that the U.S. Food and Drug Administration (FDA) approved their long-term opioid treatment,…

Chris Lange | Oct 24, 2015 at 9:40 AM EDT

8 BioPharma Movers That Cannot Be Ignored

These biotech stocks 24/7 Wall St. has picked stood out from the rest with at least 25% gains over the…

Paul Ausick | Oct 21, 2015 at 4:04 PM EDT

The 52-Week Low Club for Wednesday

October 21, 2015: Here are four stocks trading with heavy volume among 94 equities making new 52-week lows today. Valeant…

Chris Lange | Oct 3, 2015 at 9:15 AM EDT

5 Big FDA Decisions Expected in October

24/7 Wall St. has collected several big FDA decisions coming up on the calendar for the month of October and…

Jon C. Ogg | Sep 29, 2015 at 8:55 AM EDT

Top Analyst Upgrades and Downgrades: Ambarella, Apple, Bunge, McDonald’s, Micron, Occidental and Many More

Tuesday's top analyst upgrades, downgrades and initiations include Ambarella, Apple, Bunge, McDonald's, Micron Technology and Occidental Petroleum.

1 2 3 4 5 6 7

Endo Health Solutions : ENDP

All ENDP Articles

The 52-Week Low Club for Tuesday

The 52-Week Low Club for Thursday

The 52-Week Low Club for Monday

Top Analyst Upgrades and Downgrades: GE, 3M, Shopify, SunPower, Zafgen, CIT, Ericsson, Honeywell and Many More

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016

Top RBC Stock Picks With as Much as 100% Upside Potential

Top Analyst Upgrades and Downgrades: Best Buy, CA, Deere, Eli Lilly, Ferrari, Netflix, Oracle, Salesforce.com and More

10 Worst Performing Stocks in October

6 BioPharma Movers That Cannot Be Ignored

With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains

How an FDA Approval Changes the Game for Endo and BioDelivery Sciences

8 BioPharma Movers That Cannot Be Ignored

The 52-Week Low Club for Wednesday

5 Big FDA Decisions Expected in October

Top Analyst Upgrades and Downgrades: Ambarella, Apple, Bunge, McDonald’s, Micron, Occidental and Many More

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

Endo Health Solutions : ENDP

All ENDP Articles

The 52-Week Low Club for Tuesday

The 52-Week Low Club for Thursday

The 52-Week Low Club for Monday

Top Analyst Upgrades and Downgrades: GE, 3M, Shopify, SunPower, Zafgen, CIT, Ericsson, Honeywell and Many More

RBC Out With Top Specialty Pharmaceutical Stocks to Buy for 2016

Top RBC Stock Picks With as Much as 100% Upside Potential

Top Analyst Upgrades and Downgrades: Best Buy, CA, Deere, Eli Lilly, Ferrari, Netflix, Oracle, Salesforce.com and More

10 Worst Performing Stocks in October

6 BioPharma Movers That Cannot Be Ignored

With Specialty Pharmaceuticals Down Big, 3 to Buy Now for Huge Potential Gains

How an FDA Approval Changes the Game for Endo and BioDelivery Sciences

8 BioPharma Movers That Cannot Be Ignored

The 52-Week Low Club for Wednesday

5 Big FDA Decisions Expected in October

Top Analyst Upgrades and Downgrades: Ambarella, Apple, Bunge, McDonald’s, Micron, Occidental and Many More

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple’s $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not

NVIDIA’s New Quantum‑AI Models Are Impressive — and the Market Doesn’t Seem Ready to Price the Step‑Change

Featured Reads

A 70-Year-Old With $1.4 Million Faces a $62,000 RMD That Pushes Him Into a Higher Tax Bracket

A Couple's $1.2 Million Portfolio Faces a 3.9% Withdrawal Rate That Feels Safe but Is Not